{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:51:45Z","timestamp":1791568305460,"version":"4.3.4"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:00:00Z","timestamp":1790726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"New Taipei Municipal TuCheng Hospital"},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPVVL0041"],"award-info":[{"award-number":["CORPVVL0041"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"publisher","award":["NSTC 112-2314-B-182A-111-MY3"],"award-info":[{"award-number":["NSTC 112-2314-B-182A-111-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate the association between radioactive iodine (RAI) treatment and the subsequent risk of second primary malignancies (SPMs) in thyroid cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Population-based propensity score-matched retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Data were obtained from the National Health Insurance Research Database, Cancer Registry, and Death Registry in Taiwan between 2001 and 2021. SPM was defined as any primary malignancy diagnosed more than one year following RAI treatment. Subdistribution hazard ratios (SHRs) with 95% confidence intervals (CIs) were estimated using a competing-risks survival analysis, adjusted for age, sex, and the Charlson comorbidity index (CCI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 60 479 patients with thyroid cancer were identified. Following propensity score matching for sex, age, and CCI, the study cohort comprised 16 967 patients who received RAI and 16 967 patients who did not. RAI treatment was significantly associated with increased risk of salivary gland cancer (adjusted SHR, 2.87; 95% CI, 1.14-7.23; P, .026) and leukemia (adjusted SHR, 2.76; 95% CI, 1.23-6.20; P, .014). In addition, a 30-mCi increase in RAI dose was significantly associated with a higher risk of salivary gland cancer (adjusted SHR, 1.03; 95% CI, 1.01-1.06; P, .017) and leukemia (adjusted SHR, 1.04; 95% CI, 1.02-1.07; P &amp;lt; .001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Thyroid cancer patients treated with RAI have a significantly increased risk of developing salivary gland cancer and leukemia.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ejendo\/lvag187","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:39:19Z","timestamp":1790681959000},"page":"600-610","source":"Crossref","is-referenced-by-count":0,"title":["Second primary malignancy risk following radioactive iodine therapy for thyroid cancer: a population-based matched cohort study in Taiwan"],"prefix":"10.1093","volume":"195","author":[{"given":"Shu-Fu","family":"Lin","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, New Taipei Municipal TuCheng Hospital (Built and Operated by Chang Gung Medical Foundation) , New Taipei City 236052 ,","place":["Taiwan"]},{"name":"College of Medicine, Chang Gung University , Taoyuan City 333323 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ling","family":"Lu","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Main Branch , Taoyuan City 33305 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Ling","family":"Wu","sequence":"additional","affiliation":[{"name":"Center for Big Data Analytics and Statistics, Chang Gung Memorial Hospital, Linkou Main Branch , Taoyuan City 33302 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-2344","authenticated-orcid":false,"given":"Shang-Hung","family":"Chang","sequence":"additional","affiliation":[{"name":"College of Medicine, Chang Gung University , Taoyuan City 333323 ,","place":["Taiwan"]},{"name":"Cardiovascular Division, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou Main Branch , Taoyuan City 33305 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10065 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3224-7238","authenticated-orcid":false,"given":"Yu-Tung","family":"Huang","sequence":"additional","affiliation":[{"name":"National Center for Geriatrics and Welfare Research, National Health Research Institutes , Yunlin County 632007 ,","place":["Taiwan"]},{"name":"Graduate Institute of Life Sciences, College of Biomedical Sciences, National Defense Medical University , Taipei City 114201 ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,30]]},"reference":[{"issue":"10387","key":"2026100913013932400_lvag187-B1","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"2026100913013932400_lvag187-B2","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"2026100913013932400_lvag187-B3","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdp050","article-title":"Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution","volume":"20","author":"Sciuto","year":"2009","journal-title":"Ann Oncol"},{"issue":"8","key":"2026100913013932400_lvag187-B4","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026100913013932400_lvag187-B5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jama.2011.1139","article-title":"Use of radioactive iodine for thyroid cancer","volume":"306","author":"Haymart","year":"2011","journal-title":"JAMA"},{"issue":"1","key":"2026100913013932400_lvag187-B6","doi-asserted-by":"publisher","first-page":"e210046","DOI":"10.1530\/ETJ-21-0046","article-title":"2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?","volume":"11","author":"Pacini","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"1","key":"2026100913013932400_lvag187-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"3","key":"2026100913013932400_lvag187-B8","first-page":"362","article-title":"False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer","volume":"2","author":"Oh","year":"2012","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"3","key":"2026100913013932400_lvag187-B9","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","article-title":"The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics","volume":"135","author":"Kogai","year":"2012","journal-title":"Pharmacol Ther"},{"issue":"9","key":"2026100913013932400_lvag187-B10","first-page":"1188","article-title":"Sodium iodide symporter: its role in nuclear medicine","volume":"43","author":"Chung","year":"2002","journal-title":"J Nucl Med"},{"issue":"4","key":"2026100913013932400_lvag187-B11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1530\/eje.1.02257","article-title":"A perspective view of sodium iodide symporter research and its clinical implications","volume":"155","author":"Riesco-Eizaguirre","year":"2006","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"2026100913013932400_lvag187-B12","first-page":"1191","article-title":"Clinical significance of hepatic visualization on iodine-131 whole-body scan in patients with thyroid carcinoma","volume":"38","author":"Chung","year":"1997","journal-title":"J Nucl Med"},{"issue":"4","key":"2026100913013932400_lvag187-B13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1053\/j.semnuclmed.2024.05.002","article-title":"Radioactive iodine therapy in differentiated thyroid cancer: an update on dose recommendations and risk of secondary primary malignancies","volume":"54","author":"Nguyen","year":"2024","journal-title":"Semin Nucl Med"},{"issue":"9","key":"2026100913013932400_lvag187-B14","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1038\/sj.bjc.6601319","article-title":"Second primary malignancies in thyroid cancer patients","volume":"89","author":"Rubino","year":"2003","journal-title":"Br J Cancer"},{"issue":"19","key":"2026100913013932400_lvag187-B15","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1002\/cncr.26070","article-title":"Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy","volume":"117","author":"Iyer","year":"2011","journal-title":"Cancer"},{"issue":"2","key":"2026100913013932400_lvag187-B16","doi-asserted-by":"publisher","first-page":"djv314","DOI":"10.1093\/jnci\/djv314","article-title":"Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study","volume":"108","author":"Teng","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"2026100913013932400_lvag187-B17","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1200\/JCO.21.01841","article-title":"Association between radioactive iodine treatment for pediatric and young adulthood differentiated thyroid cancer and risk of second primary malignancies","volume":"40","author":"Pasqual","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"2026100913013932400_lvag187-B18","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1200\/JCO.2017.75.0232","article-title":"Risk of hematologic malignancies after radioiodine treatment of well-differentiated thyroid cancer","volume":"36","author":"Molenaar","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026100913013932400_lvag187-B19","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1089\/thy.2016.0037","article-title":"Incidence of nonthyroidal primary malignancy and the association with (131)I treatment in patients with differentiated thyroid cancer","volume":"26","author":"Hirsch","year":"2016","journal-title":"Thyroid"},{"key":"2026100913013932400_lvag187-B20","doi-asserted-by":"publisher","first-page":"e2018062","DOI":"10.4178\/epih.e2018062","article-title":"Data resource profile: the national health insurance research database (NHIRD)","volume":"40","author":"Lin","year":"2018","journal-title":"Epidemiol Health"},{"key":"2026100913013932400_lvag187-B21","doi-asserted-by":"publisher","first-page":"349","DOI":"10.2147\/CLEP.S196293","article-title":"Taiwan's national health insurance research database: past and future","volume":"11","author":"Hsieh","year":"2019","journal-title":"Clin Epidemiol"},{"key":"2026100913013932400_lvag187-B22","doi-asserted-by":"publisher","first-page":"791826","DOI":"10.3389\/fendo.2022.791826","article-title":"Risk factors and prognosis for metastatic follicular thyroid cancer","volume":"13","author":"Wu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026100913013932400_lvag187-B23","doi-asserted-by":"publisher","first-page":"102867","DOI":"10.1016\/j.canep.2025.102867","article-title":"Comorbidity burden and risk of second primary non-breast cancer in breast cancer survivors","volume":"97","author":"Mukherjee","year":"2025","journal-title":"Cancer Epidemiol"},{"issue":"3","key":"2026100913013932400_lvag187-B24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/BSD.0000000000000932","article-title":"Propensity score matching: a statistical method","volume":"33","author":"Kane","year":"2020","journal-title":"Clin Spine Surg"},{"issue":"27","key":"2026100913013932400_lvag187-B25","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine\u2013Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"issue":"3","key":"2026100913013932400_lvag187-B26","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3390\/cancers17030378","article-title":"A pan-cancer analysis of age and sex differences in cancer incidence and survival in the United States, 2001-2020","volume":"17","author":"Selvaraj","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026100913013932400_lvag187-B27","doi-asserted-by":"publisher","first-page":"k134","DOI":"10.1136\/bmj.k134","article-title":"Cancer risk associated with chronic diseases and disease markers: prospective cohort study","volume":"360","author":"Tu","year":"2018","journal-title":"BMJ"},{"issue":"4","key":"2026100913013932400_lvag187-B28","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1210\/jc.2014-4332","article-title":"Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer","volume":"100","author":"Ruel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026100913013932400_lvag187-B29","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1677\/erc.1.01320","article-title":"Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition","volume":"13","author":"Chow","year":"2006","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2026100913013932400_lvag187-B30","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jso.20656","article-title":"Survival in patients with papillary thyroid cancer is not affected by the use of radioactive isotope","volume":"96","author":"Podnos","year":"2007","journal-title":"J Surg Oncol"},{"issue":"12","key":"2026100913013932400_lvag187-B31","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"issue":"7495","key":"2026100913013932400_lvag187-B32","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1016\/S0140-6736(67)91475-4","article-title":"Chewing tobacco and radioiodine","volume":"289","author":"McCall","year":"1967","journal-title":"Lancet"},{"issue":"10","key":"2026100913013932400_lvag187-B33","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1177\/0022034509343143","article-title":"Sensitivity of salivary glands to radiation: from animal models to therapies","volume":"88","author":"Grundmann","year":"2009","journal-title":"J Dent Res"},{"issue":"5","key":"2026100913013932400_lvag187-B34","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1089\/thy.2012.0106","article-title":"Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms","volume":"23","author":"Jeong","year":"2013","journal-title":"Thyroid"},{"issue":"10","key":"2026100913013932400_lvag187-B35","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1118\/1.3602459","article-title":"Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer","volume":"38","author":"Liu","year":"2011","journal-title":"Med Phys"},{"issue":"7","key":"2026100913013932400_lvag187-B36","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005537-199807000-00026","article-title":"Increased risk of salivary gland tumors after low-dose irradiation","volume":"108","author":"Modan","year":"1998","journal-title":"Laryngoscope"},{"key":"2026100913013932400_lvag187-B37","doi-asserted-by":"publisher","first-page":"101017","DOI":"10.1016\/j.blre.2022.101017","article-title":"Radiation and leukaemia: which leukaemias and what doses?","volume":"58","author":"Gale","year":"2023","journal-title":"Blood Rev"},{"issue":"7","key":"2026100913013932400_lvag187-B38","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S2352-3026(15)00094-0","article-title":"Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study","volume":"2","author":"Leuraud","year":"2015","journal-title":"Lancet Haematol"},{"issue":"2","key":"2026100913013932400_lvag187-B39","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.jncc.2022.01.001","article-title":"Low-dose ionizing radiation exposure and risk of leukemia: results from 1950-1995 Chinese medical X-ray workers' cohort study and meta-analysis","volume":"2","author":"Gu","year":"2022","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"2026100913013932400_lvag187-B40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/jnci\/djad040","article-title":"Linear association between radioactive iodine dose and second primary malignancy risk in thyroid cancer","volume":"115","author":"Kim","year":"2023","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"2026100913013932400_lvag187-B41","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1249\/MSS.0000000000001937","article-title":"Physical activity in cancer prevention and survival: a systematic review","volume":"51","author":"McTiernan","year":"2019","journal-title":"Med Sci Sports Exerc"},{"issue":"3","key":"2026100913013932400_lvag187-B42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3390\/nu17030503","article-title":"Dietary restrictions and cancer prevention: state of the art","volume":"17","author":"Caprara","year":"2025","journal-title":"Nutrients"},{"issue":"7","key":"2026100913013932400_lvag187-B43","doi-asserted-by":"publisher","first-page":"e461","DOI":"10.1016\/S2468-2667(24)00107-5","article-title":"Alcohol rehabilitation and cancer risk: a nationwide hospital cohort study in France","volume":"9","author":"Schwarzinger","year":"2024","journal-title":"Lancet Public Health"},{"issue":"2","key":"2026100913013932400_lvag187-B44","doi-asserted-by":"publisher","first-page":"e2354958","DOI":"10.1001\/jamanetworkopen.2023.54958","article-title":"Cancer risk following smoking cessation in Korea","volume":"7","author":"Park","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2026100913013932400_lvag187-B45","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1530\/EJE-13-0309","article-title":"Second primary malignancies following thyroid cancer: a population-based study in Taiwan","volume":"169","author":"Lu","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"2026100913013932400_lvag187-B46","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-18810-7","volume-title":"Radiobiology Textbook","author":"Baatout","year":"2023"},{"issue":"5","key":"2026100913013932400_lvag187-B47","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/path.5389","article-title":"Radiation-induced tissue damage and response","volume":"250","author":"McBride","year":"2020","journal-title":"J Pathol"},{"issue":"Supplement 3","key":"2026100913013932400_lvag187-B48","doi-asserted-by":"publisher","first-page":"23S","DOI":"10.2967\/jnumed.121.262751","article-title":"Normal-tissue tolerance to radiopharmaceutical therapies, the knowns and the unknowns","volume":"62","author":"Wahl","year":"2021","journal-title":"J Nucl Med"},{"issue":"11","key":"2026100913013932400_lvag187-B49","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1007\/s00259-023-06295-0","article-title":"Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project","volume":"50","author":"Taprogge","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026100913013932400_lvag187-B50","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1590\/1807-3107bor-2025.vol39.014","article-title":"Principles of radiological protection and application of ALARA, ALADA, and ALADAIP: a critical review","volume":"39","author":"Mendon\u00e7a","year":"2025","journal-title":"Braz Oral Res"},{"issue":"3","key":"2026100913013932400_lvag187-B51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"12","key":"2026100913013932400_lvag187-B52","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","article-title":"Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"30","author":"Filetti","year":"2019","journal-title":"Ann Oncol"},{"issue":"6","key":"2026100913013932400_lvag187-B53","doi-asserted-by":"publisher","first-page":"e2402","DOI":"10.1210\/clinem\/dgab139","article-title":"Multilevel factors associated with more intensive use of radioactive iodine for low-risk thyroid cancer","volume":"106","author":"Wallner","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"suppl 3","key":"2026100913013932400_lvag187-B54","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1016\/j.jfma.2024.07.030","article-title":"Reflection on 30 years of Taiwanese national health insurance: analysis of Taiwanese health system progress, challenges, and opportunities","volume":"123","author":"Tsuei","year":"2024","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"2026100913013932400_lvag187-B55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11764-021-01009-7","article-title":"The characteristics of patients who quit smoking in the year following a cancer diagnosis","volume":"16","author":"Gummerson","year":"2022","journal-title":"J Cancer Surviv"},{"issue":"3","key":"2026100913013932400_lvag187-B56","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1210\/jc.2014-3169","article-title":"Cancer-related worry in Canadian thyroid cancer survivors","volume":"100","author":"Bresner","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"2026100913013932400_lvag187-B57","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.3390\/cancers13163955","article-title":"Survival and death causes in thyroid cancer in Taiwan: a nationwide case-control cohort study","volume":"13","author":"Lu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026100913013932400_lvag187-B58","author":"Health Promotion Administration"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/advance-article-pdf\/doi\/10.1093\/ejendo\/lvag187\/71493181\/lvag187.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/4\/600\/71493181\/lvag187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/195\/4\/600\/71493181\/lvag187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:01:43Z","timestamp":1791565303000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/195\/4\/600\/8850001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,30]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvag187","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,30]]}}}